Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (41-50 of 487) with videos related to

Pageof 49
Sort By:
Cancer Research|October 2, 2023
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and BeyondJie Wu, Vivek Subbiah
Oncology|October 13, 2020
Sequencing PEComas: Viewing Unicorns through the Molecular Looking GlassRoman Groisberg, Vivek Subbiah
Trends in Cancer|February 21, 2018
Challenging Standard-of-Care Paradigms in the Precision Oncology EraVivek Subbiah, Razelle Kurzrock
JAMA Oncology|April 15, 2016
Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the DiagnosisVivek Subbiah, Razelle Kurzrock
Translational Gastroenterology and Hepatology|November 24, 2017
The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?Roman Groisberg, Vivek Subbiah
Oncoscience|June 16, 2023
Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancerDeepak Bhamidipati, Vivek Subbiah
The Lancet. Oncology|October 9, 2020
EZH2 inhibition for epithelioid sarcoma and follicular lymphomaRoman Groisberg, Vivek Subbiah
Cell Reports. Medicine|September 27, 2023
Clinical development and management of adverse events associated with FGFR inhibitorsVivek Subbiah, Srdan Verstovsek
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2021
Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole GameRoman Groisberg, Vivek Subbiah
Trends in Cancer|May 11, 2020
Managing Cancer Care during the COVID-19 Pandemic and BeyondOmar Alhalabi, Vivek Subbiah
Pageof 49

Showing results (41-50 of 487) with videos related to

Sort By:
Pageof 49
Cancer Research|October 2, 2023
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and BeyondJie Wu, Vivek Subbiah
Oncology|October 13, 2020
Sequencing PEComas: Viewing Unicorns through the Molecular Looking GlassRoman Groisberg, Vivek Subbiah
Trends in Cancer|February 21, 2018
Challenging Standard-of-Care Paradigms in the Precision Oncology EraVivek Subbiah, Razelle Kurzrock
JAMA Oncology|April 15, 2016
Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the DiagnosisVivek Subbiah, Razelle Kurzrock
Translational Gastroenterology and Hepatology|November 24, 2017
The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?Roman Groisberg, Vivek Subbiah
Oncoscience|June 16, 2023
Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancerDeepak Bhamidipati, Vivek Subbiah
The Lancet. Oncology|October 9, 2020
EZH2 inhibition for epithelioid sarcoma and follicular lymphomaRoman Groisberg, Vivek Subbiah
Cell Reports. Medicine|September 27, 2023
Clinical development and management of adverse events associated with FGFR inhibitorsVivek Subbiah, Srdan Verstovsek
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2021
Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole GameRoman Groisberg, Vivek Subbiah
Trends in Cancer|May 11, 2020
Managing Cancer Care during the COVID-19 Pandemic and BeyondOmar Alhalabi, Vivek Subbiah
Pageof 49